Modafinil is a prescription wakefulness-promoting medication used to improve wakefulness in clinically appropriate adults. It requires evaluation by a licensed provider and is not appropriate for everyone.

Yes. Modafinil is a prescription medication that may be prescribed by a licensed healthcare provider when clinically appropriate. Eligibility is determined based on medical history, symptoms, and provider evaluation.

Yes. Modafinil is a Schedule IV controlled substance in the US and requires a valid prescription from a licensed provider.

Common side effects include headache, nausea, dry mouth, and insomnia if taken too late in the day. Rare but serious: Stevens-Johnson syndrome has been reported. Discontinue immediately and seek emergency care if you develop a rash, blistering, or mucosal lesions.

Not recommended for patients with a history of hypersensitivity to modafinil or armodafinil, left ventricular hypertrophy, or those with cardiac arrhythmias.

Modafinil induces CYP3A4 and may reduce effectiveness of hormonal contraceptives, cyclosporine, and certain antiretrovirals. Full medication review is required.

Patients with hepatic impairment require dose reduction. History of psychosis or mania warrants careful provider evaluation before prescribing.

Provigil® is the original brand name for Modafinil. Generic Modafinil contains the same active ingredient and is required to meet FDA standards for quality, strength, and effectiveness.

Generic Modafinil contains the same active ingredient as Provigil® and is required by the FDA to demonstrate bioequivalence to the brand-name medication.

Stop taking modafinil and contact a healthcare provider immediately. It is not always possible to predict whether a rash will progress into a serious reaction such as SJS, TEN, or DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Prompt medical assessment is recommended for any unexplained rash that develops during treatment.

Modafinil and caffeine work differently in the body. Coffee typically provides shorter-lasting stimulation, while Modafinil is a prescription wakefulness-promoting medication that may provide effects lasting significantly longer.

Some individuals use Modafinil under medical supervision without relying heavily on caffeine. However, patients should follow their provider's recommendations regarding caffeine consumption and medication use.

Modafinil is a prescription medication designed to promote wakefulness, while energy drinks typically rely on caffeine and other stimulatory ingredients. They are not considered interchangeable products.

Many users report a smoother wakefulness experience compared to caffeine or energy drinks. However, individual responses vary and some patients may experience fatigue as the medication wears off.

Modafinil is a wakefulness-promoting medication approved for specific sleep disorders, while Adderall is an amphetamine-based stimulant approved for ADHD and narcolepsy. They have different mechanisms of action, indications, and side effect profiles.

Both medications have potential risks and benefits. The most appropriate treatment depends on a patient's diagnosis, medical history, and healthcare provider's assessment.

Some patients report improved alertness, concentration, and productivity while taking Modafinil. Individual results vary, and the medication should only be used under medical supervision.

Modafinil is not FDA-approved for ADHD. However, healthcare providers may determine whether alternative treatment options are appropriate based on an individual's clinical situation.

Modafinil has an elimination half-life of approximately 12 to 15 hours. Complete elimination may take several days depending on dosage, metabolism, age, and overall health.

Standard workplace drug screens do not typically test for Modafinil. However, specialized testing may detect the medication.

Yes. Some individuals may experience anxiety, nervousness, agitation, or restlessness while taking Modafinil.

Modafinil may increase blood pressure and heart rate in some individuals. Patients with cardiovascular conditions should discuss potential risks with their healthcare provider.

Yes. Taking Modafinil too late in the day may interfere with sleep. Patients should follow their prescribed dosing schedule.

Patients should consult their healthcare provider regarding alcohol use while taking Modafinil, as alcohol may increase certain side effects or affect wakefulness.

Modafinil has a lower abuse potential than traditional stimulant medications but remains a Schedule IV controlled substance due to the potential for misuse and dependence.

Blood work is not always required. Depending on the patient's medical history, providers may recommend a CBC, CMP, liver function testing, kidney function testing, thyroid testing, or other evaluations before treatment.

Rare but serious adverse reactions may include severe allergic reactions, angioedema, psychiatric symptoms, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Patients should seek immediate medical attention if signs of a serious skin reaction develop.

Depending on provider protocols, prescription fulfillment may be performed through licensed U.S. pharmacies, including pharmacies such as Empower Pharmacy and Strive Pharmacy, subject to availability, state regulations, and provider discretion.

Some patients take Modafinil daily under healthcare provider supervision for approved medical conditions. Patients should use the medication exactly as prescribed.

Yes. Modafinil is FDA-approved to improve wakefulness in adults with Shift Work Sleep Disorder when prescribed by a licensed healthcare provider.

Modafinil is intended for medically appropriate use under provider supervision. Patients should not use Modafinil to intentionally avoid necessary sleep without medical guidance.

Long-term treatment should be monitored by a healthcare provider. Regular follow-up evaluations help assess effectiveness, side effects, cardiovascular health, and ongoing treatment needs.

Modafinil should be used cautiously in individuals with significant cardiovascular disease. Some international prescribing information advises against use in patients with uncontrolled moderate-to-severe hypertension, certain cardiac arrhythmias, or specific structural heart conditions. Patients with a history of heart disease should discuss risks with their healthcare provider before starting treatment.

Modafinil may worsen or trigger psychiatric symptoms in susceptible individuals, including anxiety, agitation, mania, hallucinations, or psychosis. Patients with a history of bipolar disorder, psychosis, or severe psychiatric illness should be monitored closely and discuss potential risks with their prescribing provider.

No. Because modafinil and armodafinil are closely related compounds, a history of hypersensitivity to either medication is generally considered a contraindication to use.

Seek immediate medical attention if you experience rash, facial swelling, swelling of the lips or tongue, difficulty breathing, fever, swollen lymph nodes, mouth sores, skin blistering, or signs of organ involvement such as jaundice or severe fatigue. These symptoms may indicate a serious hypersensitivity reaction requiring urgent treatment.

Serious dermatologic reactions, including possible cases of Stevens-Johnson Syndrome and multiorgan hypersensitivity reactions, were observed during pediatric clinical trials. Because of these safety concerns, modafinil is not approved for pediatric patients in the United States.

No. Modafinil promotes wakefulness but is not a substitute for adequate sleep. Patients should continue practicing good sleep hygiene and address underlying sleep disorders as directed by their healthcare provider.

Broughton RJ, Fleming JA, George CF. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-51.

Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001

Provigil (modafinil) package insert. Frazer, PA: Cephalon; 2015 Jan.

Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol

Neurosurg Psychiatry 2002;72:179-183.

Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil. Clin Neuropharmacol 2002;25:111-114.

DeBattista C, Doghramji K, Menza MA, et al; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:1057-1064.

Fava M, Thase ME, DeBattista C, et al. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93.

Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031-1040.

Arnold VK, Feifel D, Earl CQ, et al. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2014;18:133-144. Epub 2012 May 22.

Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy. JAMA Intern Med 2020; Published online Oct. 19, 2020. doi:10.1001/jamainternmed.2020.4009.

Hackett LP, Kristensen JH, Hale TW, et al. Methylphenidate and breast-feeding. Ann Pharmacother 2006;40:1890-1.

Spigset O, Brede WR, Zahlsen K. Excretion of methylphenidate in breast milk. Am J Psychiatry 2007;164:348

American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.

Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116:777-84

Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4:561-72